Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study

Azar, Sami T.; Hantash, Hadi Abu; Jambart, S; El-Zaheri, Mohamed M.; Rachoin, Rachoin; Chalfoun, Amal; Lahoud, Layla; Okkeh, Osama; Bramlage, Peter; Brudi, Philippe; Ambegaonkar, Baishali

doi:10.2147/vhrm.s57194

Cited by 8 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study, Jordanian individuals who were advised about dietary recommendations had a much higher likelihood of maintaining a healthy diet; thus, physicians should teach their patients about the importance of healthy lifestyles and eating habits [ 63 ]. In a cross-sectional, retrospective, multi-centered study conducted on Jordanian and Lebanese patients treated previously with statins, it was found that smoking, DM, and CHD were significant independent risk factors for not achieving optimal LDL-C level goals [ 67 ].…”

Section: Resultsmentioning

confidence: 99%

A Jordanian Multidisciplinary Consensus Statement on the Management of Dyslipidemia

Al Mousa,

Al-Azzam,

Araydah

et al. 2023

JCM

View full text Add to dashboard Cite

Atherosclerotic cardiovascular disease (ASCVD) is the primary contributor to global mortality rates, which significantly escalates healthcare expenditures. Risk factors for ASCVD (including dyslipidemia) frequently present in clusters rather than separately. Addressing these risk factors is crucial in the early initiation of a comprehensive management plan that involves both lifestyle modifications and pharmacotherapy to reduce the impact of ASCVD. A team of Jordanian professionals from various medical organizations and institutes took the initiative to create a set of guidelines for dyslipidemia screening and therapy. A detailed, comprehensive literature review was undertaken utilizing several databases and keywords. This consensus statement provides recommendations for dyslipidemia management in Jordanians on several issues including cardiovascular risk estimation, screening eligibility, risk categories, treatment goals, lifestyle changes, and statin and non-statin therapies. It is recommended that all Jordanian individuals aged 20 years old or older undergo lipid profile testing. This should be followed by determining the level of cardiovascular risk depending on the presence or absence of ASCVD and cardiovascular risk factors, eligibility for lipid-lowering therapy, and the target low-density cholesterol serum level to be achieved. In conclusion, prioritizing the management of dyslipidemia is of the utmost importance in improving public health and reducing the burden of cardiovascular diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

A Jordanian Multidisciplinary Consensus Statement on the Management of Dyslipidemia

Al Mousa,

Al-Azzam,

Araydah

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…A previous cross-sectional study in Lebanese and Jordanian dyslipidemic patients reported that rosuvastatin was the third most used statin (21.2%) in these populations. 20 The same study, however, reported that LDL-C goals were not achieved in 67.2% of patients with very high cardiovascular risk. It is hoped that with the cost saving of using a generic form of this potent statin, the use of this agent will increase, helping a greater proportion of patients achieve their target LDL-C goals.…”

Section: Discussionmentioning

confidence: 96%

Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients

Betto

Fares

Saliba

et al. 2017

Annals of Saudi Medicine

View full text Add to dashboard Cite

BACKGROUNDNo published studies have assessed the efficacy and safety of rosuvastatin generics.OBJECTIVESPrimary objective to assess the safety and efficacy of a generic rosuvastatin in reducing plasma low-density-lipoprotein cholesterol (LDL-C) in Lebanese dyslipidemic patients. Changes in high-density lipoprotein cholesterol, triglycerides and adverse effects were secondary objectives.DESIGNProspective, observational, non-comparative.SETTINGMultiple outpatient clinics in Lebanon.PATIENTS AND METHODSDyslipidemic patients requiring statin therapy were followed for 2 months after prescription of a generic rosuvastatin at the physician’s discretion. Efficacy and safety measurements were collected from medical records.MAIN OUTCOME MEASURE(S)Efficacy was assessed based on the evaluation of mean and percent change in LDL-C between baseline and week 8 as well as the proportion of patients reaching target LDL-C levels. Safety was assessed based on the evaluation of the incidence of adverse events (AEs) during the study period.RESULTSTwo months after initiation of generic rosuvastatin, LDL-C levels in the 313 eligible patients who completed the study significantly decreased from 4.3 (0.8) mmol/L (168.2 [31.3] mg/dL) at baseline to 2.7 (0.7) mmol/L (105.9 [25.5] mg/dL) (P<.001). The mean percent change in LDL-C level was highest in subjects receiving generic rosuvastatin at a dose of 40 mg/day (−47.4%), followed by 20 mg/day (−36.8%), and 10 mg/day (−31.4%); 82.5% of patients reached the target LDL-C level as set by their physician at baseline. Thirteen patients (4%) reported six AEs during treatment: abdominal pain, headache, stomach ache, insomnia, musculoskeletal pain/myalgia and nausea. No clinically significant changes in serum creatinine, serum creatine kinase, or liver function tests were reported. One patient withdrew because of an adverse event.CONCLUSIONSGeneric rosuvastatin was efficacious and safe in reducing LDL-C levels and helping the majority of patients achieve LDL-C targets after a short treatment period.LIMITATIONSThe observational nature, and a control group, and the relatively short duration of follow-up limit the generalizability of results. The authors received fees for study activities at patient visits from an independent clinical research organization subcontracted by the sponsor.

show abstract

“…Long-term dyslipidemia can lead to atherosclerosis and increase the morbidity and mortality of cardiovascular vessels. With the improvement of living standards and lifestyle changes, the number of dyslipidemia patients has increased significantly [19]. According to reports, the prevalence of dyslipidemia in Chinese adults is about 18.6%, and it is estimated that the number of patients can be as high as 160 million.…”

Section: Analysis Of Influencing Factors Of Dyslipidemiamentioning

confidence: 99%

Research on Risk Prediction of Dyslipidemia in Steel Workers Based on Recurrent Neural Network and LSTM Neural Network

Cui

Chen

et al. 2020

IEEE Access

View full text Add to dashboard Cite

With the development of medical digitization technology, artificial intelligence and big data technology, the medical model is gradually changing from treatment-oriented to prevention-oriented. In recent years, with the rise of artificial neural networks, especially deep learning, great achievements have been made in realizing image classification, natural language processing, text processing and other fields. Combining artificial intelligence and big data technology for disease risk prediction is a research focus in the field of intelligent medicine. Blood lipids are the main risk factors of cardiovascular and cerebrovascular diseases. If early prediction of abnormal blood lipids in iron and steel workers can be carried out, early intervention can be carried out, which is beneficial to protect the health of iron and steel workers. This paper around the steel workers dyslipidemia prediction problem for further study, firstly analyzes the influence factors of the steel workers dyslipidemia, discusses the commonly used method for prediction of disease, and then studied deep learning related theory, this paper introduces the two deep learning algorithms of RNN (Recurrent Neural Network) and LSTM (Long Short-Term Memory). Use the basic principle of Python language and the TensorFlow deep learning framework, establishes a prediction model based on two deep learning networks, and makes an example analysis. Experimental results show the LSTM prediction effect is superior to traditional RNN network, It provides scientific basis for the prevention of iron and steel dyslipidemia. INDEX TERMS Dyslipidemia, risk prediction, deep learning, RNN, LSTM.

show abstract

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study

Cited by 8 publications

References 33 publications

A Jordanian Multidisciplinary Consensus Statement on the Management of Dyslipidemia

A Jordanian Multidisciplinary Consensus Statement on the Management of Dyslipidemia

Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients

Research on Risk Prediction of Dyslipidemia in Steel Workers Based on Recurrent Neural Network and LSTM Neural Network

Contact Info

Product

Resources

About